Emcure Pharmaceuticals Ltd (EMCURE) — Cash Flow Quality Index
Emcure Pharmaceuticals Ltd (EMCURE) has a Cash Flow Quality Index of 0.57x as of September 2025. Operating cash flow of Rs2.56 Billion is below net income of Rs4.50 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore EMCURE operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Emcure Pharmaceuticals Ltd Cash Flow Quality Index (2022–2026)
Historical Cash Flow Quality Index for Emcure Pharmaceuticals Ltd across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Emcure Pharmaceuticals Ltd operating cash flow efficiency.
Annual Cash Flow Quality Index for Emcure Pharmaceuticals Ltd (2022–2026)
Year-by-year earnings quality comparison for Emcure Pharmaceuticals Ltd.
| Year | Quality Index | Operating CF (INR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2026 | 0.92x | Rs8.51 Billion | Rs9.24 Billion | ▲ +4.9% |
| 2025 | 0.88x | Rs8.52 Billion | Rs9.71 Billion | ▼ -60.2% |
| 2024 | 2.20x | Rs10.97 Billion | Rs4.98 Billion | ▲ +56.9% |
| 2023 | 1.40x | Rs7.47 Billion | Rs5.32 Billion | ▲ +21.0% |
| 2022 | 1.16x | Rs7.68 Billion | Rs6.62 Billion | — |